Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1

• Published in: BMC cancer Vol. 22; no. 1; pp. 1325 - 10
• Main Authors: Yamaguchi, Ou, Atarashi, Kazuyuki, Yoshimura, Kenichi, Shiono, Ayako, Mouri, Atsuhito, Nishihara, Fuyumi, Miura, Yu, Hashimoto, Kosuke, Miyamoto, Yoshiaki, Uga, Hitoshi, Seki, Nobuo, Matsushima, Tomoko, Kikukawa, Norihiro, Kobayashi, Kunihiko, Kaira, Kyoichi, Kagamu, Hiroshi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.12.2022; BioMed Central; BMC
• Subjects: Analysis; Apoptosis; B7-H1 Antigen - metabolism; Biological markers; Biomarkers; Biopsy; Blood; Cancer; Cancer immunotherapy; Carcinoma, Non-Small-Cell Lung - metabolism; Care and treatment; CD25 antigen; CD4 antigen; Chemotherapy; Diagnosis; Dosage and administration; Effector CD4+ T cells; Effector cells; Flow cytometry; Foxp3 protein; Heparin; Humans; Immune checkpoint inhibitors; Immunoregulation; Immunotherapy; Informed consent; Leukocytes, Mononuclear - metabolism; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - metabolism; Lymphocytes; Lymphocytes T; Medical examination; Monoclonal antibodies; Nitrogen; Nivolumab - pharmacology; Nivolumab - therapeutic use; Non-small cell lung cancer; Non-small cell lung carcinoma; Patient outcomes; Patients; PD-1 blockade therapy; PD-1 protein; Pembrolizumab; Peripheral blood mononuclear cells; Programmed Cell Death 1 Receptor - metabolism; Receptor antibodies; Small cell lung carcinoma; Software; T-Lymphocytes, Regulatory - metabolism; Tumors; Japan; United States > US; Biomarkers; Flow cytometry; PD-1 blockade therapy; Effector CD4+ T cells; Non-small cell lung cancer

Biomarkers that can accurately predict the efficacy of immune checkpoint inhibitors (ICIs) against programmed death 1 (PD-1) ligand in cancer immunotherapy are urgently needed. We have previously reported a novel formula that predicts the response to treatment with second-line nivolumab with high se...